Results of treatment of adult BL
Reference . | Protocol . | No. of patients treated . | Median age, y (range) . | CR, % . | DFS, % . | EFS, % . | OS, % . |
|---|---|---|---|---|---|---|---|
| Bernstein et al58 | Stanford | 18 | 25 (15-75) | 78 | 71.3 at 1 y* | N/A | 66.8 at 2 y |
| Lopez et al59 | MD Anderson 81-01 and 84-30 | 44 | 32 (17-72) | 80 | 60 at 5 y* | N/A | 52 at 5 y |
| McMaster et al10 | Vanderbilt | 20 | 44.5 (21-69) | 85 | 60 at 5 y | N/A | N/A |
| Longo et al60 | ProMACE-MOPP | 17 | 36 (19-90) | 64.7 | 61 at 15 y | N/A | 35 at 15 y |
| ProMACE-Cytabom | 8 | 100 | 86 at 15 y | N/A | 88 at 15 y | ||
| Divine et al61 | ACVBP | 52 | 34 | 85 | N/A | 47 at 5 y | 53 at 5 y |
| Soussain et al11 | LMB 81, 84, 86, and 89 | 65 | 26 (17-65) | 89 | N/A | 71 at 3 y | 74 at 3 y |
| Divine et al62 | LMB 81, 84, 86, and 89 | 51 | 33 | 83 | N/A | 61 at 2 y | 66 at 2 y |
| Hoelzer et al55 | BNHL83 | 24 | 33 (15-38) | 63 | 50 at 8 y | N/A | 49 at 8 y |
| BNHL86 | 35 | 36 (18-65) | 74 | 71 at 4 y | 51 at 4 y | ||
| Todeschini et al63 | Modified POG 8617 | 8 | 35 (19-64) | 100 | N/A | 75 at 28 mo | N/A |
| Adde et al64 | CODOX-M/IVAC | 26 | 25 (18-59) | 92.3 | N/A | 84 at 1 y | N/A |
| LaCasce et al65 | CODOX-M/IVAC | 14 | 47 | 86 | 72 at 21 mo | N/A | N/A |
| Mead et al9 | CODOX-M/IVAC | 52 | 35 (15-60) | 75 | N/A | 64.6 at 2 y | 72.8 at 2 y |
| Thomas et al56 | Hyper-CVAD | 26 | 58 (17-79) | 81 | 61 at 3 y* | N/A | 49 at 3 y |
| Cabanillas et al66 | R-Hyper-CVAD | 20 | 52 (27-77) | 89 | 86 at 1 y | N/A | N/A |
| Lee et al67 | CALGB 9251 | 54 | 44 (18-71) | 80 | 50 at 4 y | N/A | 52 at 4 y |
Reference . | Protocol . | No. of patients treated . | Median age, y (range) . | CR, % . | DFS, % . | EFS, % . | OS, % . |
|---|---|---|---|---|---|---|---|
| Bernstein et al58 | Stanford | 18 | 25 (15-75) | 78 | 71.3 at 1 y* | N/A | 66.8 at 2 y |
| Lopez et al59 | MD Anderson 81-01 and 84-30 | 44 | 32 (17-72) | 80 | 60 at 5 y* | N/A | 52 at 5 y |
| McMaster et al10 | Vanderbilt | 20 | 44.5 (21-69) | 85 | 60 at 5 y | N/A | N/A |
| Longo et al60 | ProMACE-MOPP | 17 | 36 (19-90) | 64.7 | 61 at 15 y | N/A | 35 at 15 y |
| ProMACE-Cytabom | 8 | 100 | 86 at 15 y | N/A | 88 at 15 y | ||
| Divine et al61 | ACVBP | 52 | 34 | 85 | N/A | 47 at 5 y | 53 at 5 y |
| Soussain et al11 | LMB 81, 84, 86, and 89 | 65 | 26 (17-65) | 89 | N/A | 71 at 3 y | 74 at 3 y |
| Divine et al62 | LMB 81, 84, 86, and 89 | 51 | 33 | 83 | N/A | 61 at 2 y | 66 at 2 y |
| Hoelzer et al55 | BNHL83 | 24 | 33 (15-38) | 63 | 50 at 8 y | N/A | 49 at 8 y |
| BNHL86 | 35 | 36 (18-65) | 74 | 71 at 4 y | 51 at 4 y | ||
| Todeschini et al63 | Modified POG 8617 | 8 | 35 (19-64) | 100 | N/A | 75 at 28 mo | N/A |
| Adde et al64 | CODOX-M/IVAC | 26 | 25 (18-59) | 92.3 | N/A | 84 at 1 y | N/A |
| LaCasce et al65 | CODOX-M/IVAC | 14 | 47 | 86 | 72 at 21 mo | N/A | N/A |
| Mead et al9 | CODOX-M/IVAC | 52 | 35 (15-60) | 75 | N/A | 64.6 at 2 y | 72.8 at 2 y |
| Thomas et al56 | Hyper-CVAD | 26 | 58 (17-79) | 81 | 61 at 3 y* | N/A | 49 at 3 y |
| Cabanillas et al66 | R-Hyper-CVAD | 20 | 52 (27-77) | 89 | 86 at 1 y | N/A | N/A |
| Lee et al67 | CALGB 9251 | 54 | 44 (18-71) | 80 | 50 at 4 y | N/A | 52 at 4 y |
EFS indicates event-free survival; OS, overall survival; ProMACE-MOPP, methotrexate, doxorubicin, cyclophosphamide, etoposide, mechlorethamine, vincristine, procarbazine, and prednisone; ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; LMB, French B-cell non-Hodgkin lymphoma and B-ALL protocols; NHL, German B-cell non-Hodgkin lymphoma protocols; POG, Pediatric Oncology Group; CODOX-M/IVAC, cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, high-dose cytarabine; hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine; R, rituximab; CALGB, Cancer and Leukemia Group B.
In the Stanford58 , Vanderbilt10 , and MD Anderson56 studies, these values represent 1-year relapse-free survival, 5-year freedom from progression, and 3-year continuous CR rate, respectively. DFS and EFS are not reported in these series.